Video

Episode 5 - Elucidating the Economic Burden of MS

Multiple sclerosis (MS) manifests in various subtypes, with the bulk of disability occurring among individuals with progressive disease. According to Dr. Fred Lublin, the primary drivers of burden in MS are motor dysfunction and cerebellar dysfunction, and there are numerous facets that account for the growing burden of the neurological condition. Dr. Gary Owens noted that the economic burden of MS can really be categorized into 3 phases: Phase 1 is the cost burden associated with initial presentation and the ensuing, intense diagnostic evaluation period; Phase 2 is comprised of diagnosed patients receiving disease-modifying treatments; and Phase 3 consists of patients with progressive disease and the expenditures associated with chronic care.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo